Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2-3
|
pubmed:dateCreated |
1991-4-3
|
pubmed:abstractText |
Interleukin-1 beta (IL-1 beta) has been reported to stimulate prostaglandin synthesis by the rat stomach in vitro and to inhibit gastric acid secretion in vivo. We have therefore tested the hypothesis that IL-1 beta might have protective actions in experimental models of gastroduodenal ulceration. IL-1 beta, given i.p., dose and time dependently reduced the severity of ethanol-induced gastric damage. A pretreatment time of 90 min was found to produce the greatest reduction of damage, while doses of 0.1 micrograms/kg or greater were found to produce significant effects. The protective actions of IL-1 beta were abolished by prior boiling or by pretreatment of the animals with indomethacin, and were not shared by the nonapeptide fragment 163-171. IL-1 beta also reduced the severity of gastric damage induced by indomethacin and the duodenal ulceration induced by cysteamine. The results indicate that IL-1 beta has protective actions in three separate experimental models of gastroduodenal ulceration. The mechanism of action of IL-1 beta is not entirely clear, but contributions of endogenous prostaglandin synthesis and inhibition of gastric acid secretion cannot be excluded.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cysteamine,
http://linkedlifedata.com/resource/pubmed/chemical/Ethanol,
http://linkedlifedata.com/resource/pubmed/chemical/Indomethacin,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1beta,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interleukin-1beta (163-171)
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0014-2999
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
21
|
pubmed:volume |
186
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
279-84
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2289528-Animals,
pubmed-meshheading:2289528-Cysteamine,
pubmed-meshheading:2289528-Duodenal Ulcer,
pubmed-meshheading:2289528-Ethanol,
pubmed-meshheading:2289528-Indomethacin,
pubmed-meshheading:2289528-Injections, Intraperitoneal,
pubmed-meshheading:2289528-Interleukin-1,
pubmed-meshheading:2289528-Interleukin-1beta,
pubmed-meshheading:2289528-Male,
pubmed-meshheading:2289528-Peptide Fragments,
pubmed-meshheading:2289528-Rats,
pubmed-meshheading:2289528-Rats, Inbred Strains,
pubmed-meshheading:2289528-Recombinant Proteins,
pubmed-meshheading:2289528-Stomach Ulcer
|
pubmed:year |
1990
|
pubmed:articleTitle |
Reduction of the severity of experimental gastric and duodenal ulceration by interleukin-1 beta.
|
pubmed:affiliation |
Gastrointestinal Research Group, University of Calgary, Alberta, Canada.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|